On February 1, 2022 SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported that management will present at the following upcoming investor conferences (Press release, SpringWorks Therapeutics, FEB 1, 2022, View Source [SID1234607577]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2022 Guggenheim Oncology Conference on Thursday, February 10 from 10:00-10:25 am ET.
Cowen 42nd Annual Health Care Conference on Monday, March 7 from 1:30-2:00 pm ET.
Barclays Global Healthcare Conference on Wednesday, March 16 from 9:30-10:00 am ET.
Webcasts of these events will be available on the Events & Presentations page within the Investors & Media section of the company’s website at View Source Replays of the webcasts will be available on SpringWorks’ website for a limited time following each conference.

On February 1, 2022 Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as "Dr. Reddy’s") reported that it named Akhil Ravi as CEO for its wholly-owned subsidiary Aurigene Pharmaceutical Services Ltd. (APSL) effective February 1, 2022 (Press release, Dr Reddy’s, FEB 1, 2022, View Source [SID1234607562]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Since joining Dr. Reddy’s in 2018 from McKinsey & Company, Akhil Ravi has served as Head of Strategy for Services and Active Pharmaceutical Ingredients (APIs), and headed the Sales of APIs in Europe. In addition, he has also had a brief stint as Plant Head. Akhil holds a BTech degree in Chemical Engineering from IIT Bombay and an MBA from the Indian School of Business (ISB).

"Akhil is very well prepared for this role. He was instrumental in growing our API business through product development and an improved service experience for our B2B customers through digital platforms. His strong background in customer service, sales, strategy, and management make him an ideal leader for Aurigene, and we look forward to his accomplishments in this new role." said Deepak Sapra, CEO of API and Services at Dr. Reddy’s, and Member of the Board at Aurigene.

Akhil Ravi said: "Aurigene Pharmaceutical Services is a dynamic partner for global pharma companies. With its integrated services from clinical research up to commercial manufacturing for small and large molecules, it is able to significantly speed up the journey of an NCE/NBE (New Chemical and Biological Entities) to the patient. I am very thrilled to join Aurigene and work with the team to serve innovative global pharma and biotech companies."

On February 1, 2022 Chimeric Therapeutics (ASX:CHM, "Chimeric"), a clinical-stage cell therapy company and the ASX leader in cell therapy, reported that it has signed a Sponsored Research Agreement with the University of Pennsylvania ("Penn") to support the continued research and development of CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research will be led by one of the inventors of CHM 2101, Xianxin Hua, MD, PhD. Dr Hua is a professor of Cancer Biology in Penn’s Perelman School of Medicine, and an investigator at the Abramson Family Cancer Research Institute.

The research will focus on furthering the development of CHM 2101 with preclinical studies in gastrointestinal cancers, enhancing the understanding of CHM 2101 through correlative studies and investigating CDH17 directed follow on candidates.

As part of the agreement, Chimeric has the first right of negotiation to license Penn intellectual property arising from the conduct of the sponsored research. "We are pleased to announce this research agreement as it reflects our shared commitment to the further research and development of CHM 2101 with Dr. Hua and the University of Pennsylvania," said Jennifer Chow, Chief Executive Officer of Chimeric Therapeutics.

"We are also thrilled with the progress we have made on driving this important therapy to clinic and are excited as the execution of this agreement will enhance our ability to move forward with that goal."

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper

On February 1, 2022 Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") reported the commercial availability of its novel product PEMFEXY (pemetrexed for injection) (Press release, Eagle Pharmaceuticals, FEB 1, 2022, View Source [SID1234607563]). A branded alternative to ALIMTA, Eagle’s PEMFEXY is a ready-to-use liquid with a unique J-code approved to treat nonsquamous non-small cell lung cancer and mesothelioma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’ve spent the past several months building our inventory and are pleased that PEMFEXY will now be available to the many patients who need it. Together with our recent launch of vasopressin and now PEMFEXY, these products represent significant opportunities for Eagle," stated Scott Tarriff, President and Chief Executive Officer.

In February 2020, Eagle received final approval from the U.S. Food and Drug Administration of its New Drug Application for PEMFEXY, following the settlement agreement of patent litigation with Eli Lilly and Company (NYSE: LLY) in December 2019. The agreement provided for a release of all claims by the parties and allows for an initial entry of PEMFEXY into the market (equivalent to approximately a three-week supply of current ALIMTA utilization) on February 1, 2022 and a subsequent uncapped entry on April 1, 2022.

On October 1, 2020, PEMFEXY’s Healthcare Common Procedure Coding System code, or J-code, became effective.

About PEMFEXY

PEMFEXY is a pemetrexed injection ready-to-dilute formulation for locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin; locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as maintenance treatment; locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy as a single agent; and malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery in combination with cisplatin.

On February 1, 2022 Orion Corporation reported that 38,220 A shares have been converted into 38,220 B shares (Press release, Orion , FEB 1, 2022, View Source,Register%20on%201%20February%202022. [SID1234607579]). The conversion has been entered into the Trade Register on 1 February 2022 .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,774,986 A shares and 106,359,292 B shares. The number of votes of the company’s shares is after the conversion 801,859,012.